Bolton Securities’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SMMT
BBA
KCM
Bolton Securities's SMMT Position: Q3 2026 in Review
Bolton Securities sold out of Summit Therapeutics (SMMT) in Q3 2026, closing a stake of 26,000 shares — an estimated $379K sold.
Bolton Securities first reported a position in SMMT in Q3 2025 and held it in 4 quarters. The position peaked at $379K in Q2 2026. 295 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.
- Bolton Securities reported no remaining Summit Therapeutics position as of Q3 2026 after selling out during the quarter.
- Bolton Securities sold 26,000 Summit Therapeutics shares in Q3 2026, an estimated $379K.
- Bolton Securities first reported a position in Summit Therapeutics in Q3 2025 and held it in 4 quarters.
- Bolton Securities's Summit Therapeutics position peaked at $379K in Q2 2026.
- 295 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.
Based on Bolton Securities's 13F filing for Q3 2026, filed 12 Nov 2026.